A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.
The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs).
|Eligibility criteria|| |
High grade neuroendocrine tumour or gastrointestinal adenocarcinoma with neuroendocrine features.
|Study details|| |
The treatment is Carboplatin with Abraxane. The study is investigating whether this treatment is equal to and more tolerable than the current standard of care. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW